Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Bloomberg

NZ Fin Min Willis on Economic Outlook Amid Iran War

Nicola Willis, New Zealand's Finance Minister, said she still expects the economy to grow, though at a slower pace, due to the impact of the ongoing Middle East conflict. She noted that higher fuel prices will affect local businesses as well as the broader economy. She speaks with Haidi Stroud Watts and Shery Ahn on "Bloomberg: The Asia Trade".

Leia mais: NZ Fin Min Willis on Economic Outlook Amid Iran War
Grafa

Corcept Therapeutics announces FDA approval of Lifyorli™ for platinum-resistant ovarian cancer

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company pioneering the modulation of cortisol to treat severe disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli™ (relacorilant).

Leia mais: Corcept Therapeutics announces FDA approval of Lifyorli™ for platinum-resistant ovarian cancer
Grafa

Denali Therapeutics achieves landmark FDA approval for first brain-penetrant Hunter Syndrome therapy

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company dedicated to developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm).

Leia mais: Denali Therapeutics achieves landmark FDA approval for first brain-penetrant Hunter Syndrome therapy
Grafa

Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028

Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company applying genetic insights to the development of precision medicines, reported its fourth-quarter and full-year 2025 financial results on Wednesday, March 25, 2026.

Leia mais: Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028
Grafa

ProMIS Neurosciences advances Alzheimer’s pipeline following landmark $75.5M financing

ProMIS Neurosciences (NASDAQ:PMN), a biotechnology company developing antibody therapeutics for neurodegenerative diseases, reported its full-year 2025 financial results and provided a comprehensive corporate update on March 25, 2026.

Leia mais: ProMIS Neurosciences advances Alzheimer’s pipeline following landmark $75.5M financing